登录

ZSHK Lab Raises ¥100 Million in Series A from Qiming Venture Partners

作者: Mailman 2021-08-04 15:36
沪港中科
企业数据由 动脉橙 提供支持
临床前CRO平台提供商 | A轮 | 运营中
中国-香港
2021-07-26
融资金额:RMB¥1亿
启明创投
查看

(VCBeat) July. 26, 2021 -- ZSHK Laboratories Limited ("ZSHK Lab") announced the completion of a ¥100 million Series A round of financing, led by Qiming Venture Partners, with participation from Jishi Capital. Proceeds from this round will mainly be used for laboratory construction, talent recruitment and business expansion.


According to Dr. Li Ming, founder and CEO of ZSHK Lab, ZSHK Lab was founded by the core team of the Safety Evaluation Center of Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CAS). Its main business was pre-clinical research evaluation services for biomedicine and medical devices. The company is a one-stop R&D service platform for pharmacodynamics, pharmacokinetics and safety evaluation, with headquarters in Hong Kong, China.


ZSHK Lab has set up independent laboratories in Hong Kong Science and Technology Park, Pingshan District in Shenzhen, Guangdong Province, and Suzhou Industrial Park in Jiangsu Province. At present, the pre-clinical drug evaluation service laboratory in Suzhou Industrial Park has been put into operation, the laboratory in Hong Kong Science Park (the only pre-clinical drug safety evaluation institution in Hong Kong), and the new drug and medical device evaluation laboratory in Pingshan, Shenzhen will be officially opened in the second half of this year.


>>>>

About Qiming Venture Partners


Founded in 2006, Qiming Venture Partners is a leading China venture capital firm with offices in Shanghai, Beijing, Suzhou, Shenzhen, Hong Kong, Seattle, Boston, and San Francisco Bay Area. Currently, Qiming Venture Partners manages seven US Dollar funds and five RMB funds with over US$4 billion assets under management. Qiming Venture Partners invests in information technology, new consumer business patterns, and the healthcare sector.


>>>>

About Jishi Capital


Jishi Capital is a new cutting-edge medical fund established in 2020, focusing on investment in innovative medical devices, biomedical, and related technologies. The team is jointly established by senior professionals in the medical field and investment field. It takes promoting the development of the healthcare industry as its own responsibility, and is committed to finding innovative medical products and technologies worldwide to help develop and launch products in the current Chinese market.

相关赛道 研发制造外包
注:文中如果涉及企业数据,均由受访者向分析师提供并确认。
声明:动脉网所刊载内容之知识产权为动脉网及相关权利人专属所有或持有。转载请联系tg@vcbeat.net。

Mailman

医疗行业观察者

分享
动脉橙
以上数据来自动脉橙产业智库

我们以独创的在线数据库方式,为健康产业人士提供全方位和实时的市场资讯、行业数据和分析师见解。现已覆盖数字健康、医疗器械、生物医药等近500+细分赛道,涉及公司名单、招投标、投融资信息、头部企业动态等各类数据并持续更新。

点击 【申请试用】了解动脉橙产业智库更多内容。
精彩内容推荐

医疗行业投资放缓,创业公司融资需要打几折?

【首发】稳定同位素药物研发企业鼎邦生物完成数千万元天使轮融资

总金额超百亿的288起投融资展现了产业资本怎样的医疗健康投资逻辑?

2021年Q3全球医疗健康产业资本报告:初创公司活力不减,投资维持火爆状态

Mailman

共发表文章3245篇

最近内容
  • 知之甚少:调研885名投资人后,原来美国VC们这样做决策

    2023-03-20

  • 辉瑞想要收购Seagen只是开始,这才是2023年并购的两大趋势

    2023-03-05

  • 【融资】核药企业Ratio再融资2000万美元,和拜耳合作研究新前列腺癌放射性疗法

    2023-02-09

上一篇

黑科技助推中国智能康复产业弯道超车,第二届康复与辅助技术论坛在沪举行

2021-08-04
下一篇

JYSS BIO Completes Two Rounds of Financing with Total Amount of ¥200M

2021-08-04